Permutive Raises $75M to be the Privacy-First Infrastructure for Programmatic Advertising
Permutive, an audience platform for publishers and advertisers, which enables media to be traded in a privacy-safe way, has secured $75M in Series C from SoftBank Vision Fund 2. It brings Permutive’s total raised to date to $105M, with previous investors EQT Ventures, Octopus Ventures, and ACE & Company also participating. The funding will enable Permutive to grow its patented on-device technology and scale its Audience Platform to create a global privacy-first infrastructure for programmatic advertising, now a $155B industry.
Personal data has powered digital advertising for over ten years; its misuse has captured the attention of regulators and consumers. This reckoning has triggered a seismic power shift from adtech owned programmatic advertising to a publisher owned privacy-first web. Via Permutive's Audience Platform, which has seen a 20x growth in targeted ads in the last two years, publishers can deliver a personalized advertising experience without compromising privacy via consented first-party data. The company has built a client roster comprising some of the most highly regarded publishers in Europe and North America, including News Corp, Hearst, BuzzFeed, Penske, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
“Publishers are the foundation of the web, and the relationship they have with their users is the backbone of digital advertising,” says Joe Root, CEO and co-founder, Permutive. “As privacy shifts the economics of the internet towards this publisher-owned web, a privacy-first infrastructure will ensure this next iteration of digital advertising is immune to privacy chaos, will scale, and thrive.”
Advertisers are buying directly from publishers because they are a stable foundation for data-driven advertising and are trusted partners when navigating the impact of browser changes and tightening privacy regulations. But without an infrastructure to support this transition to a publisher-owned privacy-first web, the industry won't achieve scale. Permutive has created a new model for digital advertising with privacy at its core, where publishers and advertisers can own and control their data while planning and buying campaigns. This brings transparency, scale and privacy to programmatic advertising for the first time.
“To underpin a privacy-first web requires unique technology. As a leader in on-device technology, Permutive can bring a complicated landscape that’s being significantly disrupted into a privacy-safe future. The company’s technology is now running on over 1 billion devices a month globally, and we see tremendous opportunity for sustained growth as on-device processing reshapes adtech,” says Max Ohrstrand, investor for SoftBank Investment Advisers.
Permutive’s funding comes at a critical time for the digital advertising industry. Creating a privacy-first infrastructure built to protect user privacy instils trust, transparency, and efficiency in programmatic ad spending.
Notes to editor:
Permutive is rebuilding data in programmatic advertising to protect privacy. As the only Audience Platform built on patented on-device and privacy-preserving technology, we enable premium advertisers and publishers to plan, build and activate cohorts — all while keeping everyone’s data safe.
Working with clients across Europe and North America, publishers using Permutive include News Corp, Hearst, BuzzFeed, Penske Media, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
Find out more at permutive.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients29.11.2021 17:00:00 EET | Press release
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/ “With AWS as our pre
Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants29.11.2021 16:08:00 EET | Press release
Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to respond to emerging mutants from SARS-CoV-2. Targeting newly emerging mutations of SARS-CoV-2 and using its already constructed antibody platform, Celltrion has developed a neutralising antibody cocktail consisting of CT-P63 together with its monoclonal antibody treatment Regkirona (regdanvimab, CT-P59), which was recently approved by the European Commission (EC) for the treatment of COVID-19. Celltrion enrolled 24 healthy volunteers in its global phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of CT-P63 and the company anticipates results by the end of the year. CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. Celltrion plans to evaluate neutralisation of new emerging variants tailored to specific regions and assess poten
FourKites Appoints Industry Veteran to Accelerate Supply Chain Visibility Among European Carriers and Logistics Providers29.11.2021 13:12:00 EET | Press release
Oleksii Kosenko joins FourKites®, the world’s leading real-time supply chain visibility platform, as Director Carrier Network Operations, EMEA, to accelerate the company’s rapidly growing carrier base in Europe. Prior to joining FourKites, Kosenko led the carrier sales teams at Uber Freight and sennder Technologies GmbH, and held a senior sales role at C.H. Robinson. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005303/en/ Oleksii Kosenko joins FourKites as Director Carrier Network Operations, EMEA (Photo: Business Wire) "As today’s supply chain challenges put increasing pressure on carriers across the world, my priority is to ensure that European carriers of all sizes can leverage FourKites to offer better customer service, improve cash flow and cut costs," says Kosenko. "Being able to provide a secure platform for sharing data is what will propel the entire supply chain visibility market into the future, and carrier
Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients29.11.2021 13:00:00 EET | Press release
Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction have not been disclosed. ALASTIN’s premium skincare portfolio is fully incremental to and synergistic with Galderma’s integrated dermatology platform. Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically-proven products for daily skincare regimens and peri-procedural use. ALASTIN’s product offerings are backed by its patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Since inception, ALASTIN has delivered rapid and consistent sales growth, achieving a CAGR
Celonis Accelerates its Process Mining and Execution Management Leadership in India29.11.2021 11:53:00 EET | Press release
Celonis, the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud. As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India. The opportunity for process mining and execution management in India is immense. To provide context, Eve
REPLY: “Cloud in Financial Services” Report Shows Cloud Services Transforming How Value Is Created in the Financial Services Sector29.11.2021 11:30:00 EET | Press release
“Cloud in Financial Services”, a joint report by Reply and Imperial College Business School, provides a one of a kind, in-depth look at how the cloud is set to transform financial services. “Cloud services are here to stay within financial services and the pandemic has only accelerated the move” – commented Nelson Phillips, Professor of Technology Management at the University of California (formerly Professor of Innovation and Strategy and Associate Dean of External Relations at Imperial College Business School) – “But financial institutions need to be strategic in the adoption and there are important questions that need to be addressed as firms progressively move more activity to the cloud. There are significant strategic and organisational challenges that need to be dealt with to ensure cloud adoption is successful and that firms derive maximum value from the move.” Naturally, “Cloud in Financial Services” takes these strategic and organizational challenges head on, addressing the ma
Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India29.11.2021 10:00:00 EET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection (ARI). Rad-G is a rugged, portable, handheld Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximeter and noninvasive respiration rate monitor from the pleth (RRp®). The researchers found that Rad-G was “highly acceptable among health workers” and aided the “timely classification and treatment” of pneumonia—helping them achieve correct case management in more than 91% of cases of ARI and reduce the unnecessary use of antibiotics.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211128005235/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom